Bristol-Myers Squibb (NYSE:BMS), is making its final move in
the Amylin acquisition by announcing the closure of the headquarters facility
at La Jolla, California. The work being done here will be moved to other BMS
sites and the site closure is expected to be complete by Q1 2015.
On the other hand, BMS made a recent announcement regarding
two new manufacturing facilities at Devens, Massachusetts. These two facilities
are expected to be completed in 2015 and one of these is dedicated to a group
that designs processes for early production of investigational biologics
medicines.
With several Biologics/BioPharmaceuticals in the early stage
pipeline, the move by BMS does make sense and show that the company is
preparing to march into a brighter future.
